Phentermine‑Topiramate prior authorization
Customize your policy alerts
Sign up for all careoregon policy alerts
Know when careoregon releases new policies or updates existing guidance.
Monitor payer policy activity
Prior authorization guideline for phentermine-topiramate (generic) for treatment of severe obesity, describing initial and reauthorization criteria and required documentation for CareOregon members.
No material clinical or coverage changes in this revision.
Coverage Criteria for Phentermine-Topiramate
Initial Authorization
Covered when ALL of the following are met
Review with a medical director for assessment of medical necessity/appropriateness; deny when obesity is excluded under Oregon Health Plan
Reauthorization
Covered when ALL of the following are met
Approval length for reauthorization is 12 months
This policy follows the Oregon Health Plan exclusion for obesity: obesity-related medications are not covered for adults under the Oregon Health Plan. When the request is for treatment of obesity in an adult member covered by the Oregon Health Plan, the request should be denied per plan exclusion; such cases may be referred to a medical director for review of medical necessity or appropriateness.
Clinical Thresholds and Definitions
Authorization, Documentation, and Denial Guidance
Prior authorization required; approval lengths
Prior authorization is required for generic phentermine-topiramate. Initial approvals are for 6 months; reauthorizations are for 12 months.
- Initial approval length: 6 month(s).
- Reauthorization approval length: 12 month(s).
Document failure/maximization of behavioral interventions
Provider must document that behavioral interventions were maximized and failed before approval, including motivational interviewing, health behavior and lifestyle interventions, physical activity goals, and nutrition education.
- Health behavior and lifestyle interventions must include face-to-face, family-based counseling delivering 26 or more hours over a 3–12 month period.
- Motivational interviewing, physical activity goals, and nutrition education/modifications must be documented as attempted and unsuccessful.
Medical records required with initial authorization
Submit medical records (e.g., chart notes) with the initial authorization request that document that motivational interviewing; health behavior and lifestyle interventions (including ≥26 hours over 3–12 months); physical activity goals; and nutrition education/modifications have been maximized and failed.
- Examples: chart notes showing types, duration (≥26 hours when applicable), and outcomes of behavioral interventions.
- Include documentation that these interventions were attempted and did not achieve adequate weight control.
Medical records documenting ≥5% weight loss required for reauthorization
For reauthorization, submit medical records (e.g., chart notes) documenting weight loss of at least 5% of baseline BMI.
- Documentation must show ≥5% reduction from baseline BMI during the prior authorization period.
Denial risk — OHP-excluded obesity; escalate to medical director
Deny requests for members whose obesity is excluded under the Oregon Health Plan; such cases should be reviewed with a medical director for assessment of medical necessity/appropriateness.
- Policy note: "Deny for obesity excluded under Oregon Health plan. Medications for purposes of weight loss not covered in adults."
- Escalate to a medical director when assessing medical necessity/appropriateness.
Background
Phentermine-topiramate (generic phentermine-topiramate) is authorized under this prior authorization guideline as a pharmacologic option for severe obesity when clinical criteria are met. The guideline requires documentation that comprehensive nonpharmacologic care was attempted and maximized prior to approval, including motivational interviewing, and health behavior and lifestyle interventions delivering ≥26 hours over a 3–12 month period (face-to-face, family-based counseling on nutrition and physical activity). Additional required elements include documentation of targeted physical activity goals and nutrition education/modifications (for example, reduction of sugar-sweetened beverages and improvements in healthy eating). For reauthorization the product is reviewed as a continuation therapy with an approval length of 12 months; cases where plan exclusions apply should be denied and may be escalated to a medical director.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.